INMD vs TBPH
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
InMode presents a classic 'value trap' profile, characterized by a weak Piotroski F-Score of 3/9 and a completely bearish technical trend (0/100). While the company maintains an exceptional balance sheet with virtually no debt (Debt/Equity 0.01) and extreme liquidity (Current Ratio 9.88), these strengths are offset by a severe collapse in earnings growth (-63.50% YoY). The stock trades below its Graham Number ($18.63) but above its growth-based intrinsic value ($10.01), suggesting that while it is cheap on a book-value basis, its growth trajectory is deteriorating.
TBPH presents a stable financial profile with a Piotroski F-Score of 4/9 and a valuation trading very close to its Graham Number ($16.41) and Intrinsic Value ($14.42). While the company exhibits explosive revenue growth (144.7% YoY) and an exceptionally strong liquidity position (Current Ratio 10.93), these fundamentals are countered by bearish insider sentiment and a negative technical trend. The current price of $16.72 suggests the stock is fully valued based on deterministic models, leaving little margin of safety despite the low P/E ratio.
Compare Another Pair
Related Comparisons
INMD vs TBPH: Head-to-Head Comparison
This page compares InMode Ltd. (INMD) and Theravance Biopharma, Inc. (TBPH) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.